

Special Issue

Cancer Immunotherapy: Therapeutics and Mechanisms

Message from the Guest Editors

Cancer immunotherapy has now revolutionized the field of oncology by prolonging the survival of patients. Novel treatment combinations and newly identified druggable targets will only expand the role of immunotherapy in the treatment of cancer in the decades to come. In this Special Issue, our focus is on anti-cancer immunotherapies and mechanisms of action of new immunotherapy combinations, especially those including cell therapy products. There is an urgent need to find molecular and cellular predictive and prognostic biomarkers which can be integrated with clinical pathological and imaging data to improve the prediction of both cancer progression and the response to immunotherapy for the right patient at the right time. This Special Issue will include (but is not limited to) original research and review articles on the following topics:

- Anti-cancer vaccine development and efficacy evaluation;
- Immunotherapies, adjuvants and immunomodulators;
- Cell therapy developments and mechanisms of action;
- Immunology mechanisms;
- Immune response to immunotherapies.

We look forward to receiving your contributions.

Guest Editors

Dr. Jenny Bulgarelli

IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) "Dino Amadori" S.r.l., Via Piero Maroncelli, 40, 47014 Meldola, FC, Italy

Dr. Sara Pignatta

IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) "Dino Amadori" S.r.l., Via Piero Maroncelli, 40, 47014 Meldola, FC, Italy

Deadline for manuscript submissions

closed (30 July 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/139378

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).